直肠癌同时性肝转移:联合与分期切除的目标试验模拟
该研究利用法国全国出院数据库(2014–2023)模拟目标试验,纳入1872例接受直肠与肝脏切除的直肠癌同时性肝转移患者,比较联合切除与分期切除(直肠或肝脏优先,14周内)。结果显示两组30天严重并发症和总生存无显著差异,联合手术未增加严重并发症风险,大范围肝切除独立增加严重并发症风险,手术顺序应在多学科决策中个体化。
要点
- 联合与分期切除的30天严重并发症和总生存无显著差异。
- 联合手术未增加严重并发症风险(调整OR 0.82,95%CI 0.58–1.16)。
- 大范围肝切除独立增加严重并发症风险(调整OR 1.81,95%CI 1.06–3.08)。
核心结论
- 在直肠癌同时性肝转移患者中,联合切除与分期切除的30天严重并发症发生率和长期生存相当。
- 手术顺序应在多学科团队决策中根据患者具体情况个体化选择。
研究设计与样本
- 基于法国全国出院数据库(2014–2023)模拟目标试验METASYNC-R。
- 纳入1872例接受直肠和肝脏切除的直肠癌同时性肝转移成人患者,中位年龄64岁。
- 1365例(73%)接受联合切除,507例(27%)接受分期切除(直肠或肝脏优先,14周内)。
- 采用逆概率治疗加权(IPTW)估计平均治疗效应,并用边际logistic回归和IPTW Cox模型分析结局。
主要发现
- 30天严重并发症(Clavien-Dindo≥III级)发生率联合组39.7% vs 分期组45.3%(P=0.20)。
- 联合手术与严重并发症风险无关(调整OR 0.82,95%CI 0.58–1.16;P=0.27)。
- 大范围肝切除独立增加严重并发症风险(调整OR 1.81,95%CI 1.06–3.08;P=0.029)。
- 30天死亡率联合组1.8% vs 分期组1.5%。
- 中位总生存联合组52.4个月 vs 分期组57.3个月(P=0.30),联合手术与更差生存无关(调整HR 0.88,95%CI 0.65–1.19;P=0.40),3、6、12、24个月landmark分析结果一致。
临床怎么用
- 对于可切除的直肠癌同时性肝转移,联合切除与分期切除均可作为选择,无需因担心严重并发症而排斥联合手术。
- 当计划行大范围肝切除时,应充分评估严重并发症风险,并考虑分期策略或多学科讨论。
- 手术顺序应基于患者个体情况,由多学科团队共同决策。
局限性
- 为观察性数据库模拟目标试验,可能存在未测量混杂。
- 原文未报告具体局限性的其他细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Optimal sequencing of rectal and liver resection for patients with resectable synchronous liver metastases (SLM) from rectal cancer remains controversial, and rectal-specific evidence is limited. METHODS: A nationwide target trial (METASYNC-R) was emulated using the French national discharge database (2014-2023). Adults undergoing both rectal and liver resection for rectal cancer with SLM were eligible. Combined resection was compared with staged strategies (rectum- or liver-first within 14 weeks). Inverse probability of treatment weighting (IPTW) estimated the average treatment effect. Thirty-day severe complications (Clavien-Dindo grade ≥III) were analysed using marginal logistic regression with robust variance; overall survival was analysed using IPTW Cox proportional hazards models with cluster-robust standard errors. Landmark analyses at 3, 6, 12, and 24 months addressed potential immortal time bias. RESULTS: Among 9632 patients undergoing both resections, 3057 had SLM and 1872 met the eligibility criteria (median age of 64 years); 1365 (73%) underwent combined resection and 507 (27%) underwent staged resection. Severe complications occurred in 39.7% versus 45.3% (P = 0.20); combined surgery was not associated with an increased risk of severe complications (adjusted OR 0.82 (95% c.i. 0.58 to 1.16); P = 0.27). Major hepatectomy independently increased the risk of severe complications (adjusted OR 1.81 (95% c.i. 1.06 to 3.08); P = 0.029). Thirty-day mortality was similar (1.8% versus 1.5%). Median overall survival was 52.4 months (combined) versus 57.3 months (staged) (P = 0.30). Combined surgery was not associated with worse survival (adjusted HR 0.88 (95% c.i. 0.65 to 1.19); P = 0.40), with consistent findings across landmark analyses. CONCLUSION: In this nationwide rectal cancer cohort, combined and staged strategies were associated with comparable morbidity and long-term survival. Surgical sequencing should be individualized within multidisciplinary decision-making. Combined or staged surgery for rectal cancer with liver spread: which approach is safer? Background and aim Nearly one-third of patients with rectal cancer present with liver metastases at diagnosis. When both sites can be removed, surgeons can operate in one session (combined surgery) or in two steps (staged surgery). The authors compared both strategies for safety and survival. Method The authors used data from all French hospitals (2014–2023) and found 1872 patients who had both rectal and liver surgery. The authors used a method that mimics a clinical trial, using hospital records to make the comparison as fair as possible. Findings Serious problems after surgery—needing further surgery or intensive care—occurred in about 40% of patients in both groups. Median survival was 52 months after combined surgery and 57 months after staged surgery. Neither result was clearly better. Conclusion Neither approach was clearly safer or led to better survival. The choice should be made case by case in a specialist team, based on each patient’s own case.
引用
- Marchegiani F, Dhote A, Nassar A, et al. Combined versus staged resection of synchronous rectal cancer liver metastases: national target trial emulation. Br J Surg. 2026. PMID: 42929025. doi:10.1093/bjs/znag121
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。